- Company Strengthens Leadership Team with Three Executive Hires: CFO, CTO, and VP of Biometrics and Development Strategy - SAN FRANCISCO, and HERZLIYA, Israel, Aug. 8, 2019 /PRNewswire/ -- 89Bio Ltd. (89bio), a clinical-stage biopharmaceutical company, today announced that the first patients have

- BIO89-100 was generally safe and well tolerated at all dose levels - - Robust and durable pharmacodynamic effects observed across key lipid parameters - SAN FRANCISCO and HERZLIYA, Israel, May 22, 2019 /PRNewswire/ -- 89bio LTD, a clinical-stage biopharmaceutical company focused on nonalcoholic

Data presented in Late-Breaking Presentation at the EASL International Liver Congress™ SAN FRANCISCO and HERZLIYA, Israel, April 11, 2019 /PRNewswire/ -- 89bio LTD, a clinical-stage biopharmaceutical company focused on nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders,

SAN FRANCISCO and HERZLIYA, Israel, March 28, 2019 /PRNewswire/ -- 89bio LTD, a clinical-stage biopharmaceutical company focused on nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders, today announced that preclinical data regarding BIO89-100, a novel long-acting

SAN FRANCISCO and HERZLIYA, Israel, Jan. 3, 2019 /PRNewswire/ -- 89bio, a clinical-stage biopharmaceutical company focused on nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders, today announced the appointment of Hank Mansbach, M.D., as chief medical officer.  Dr.

-Investment round led by founding investors, OrbiMed Israel and OrbiMed US, and Longitude Capital, with participation by RA Capital Management and Pontifax- -Company acquires NASH assets from Teva, initiates Phase 1 clinical trial- -Rohan Palekar, former Avanir Pharmaceuticals CEO, joins 89Bio as